Manufacturing expertise and leading partnerships
Our ability to accelerate the delivery of innovative gene therapies is enabled by preferred partnerships with leading manufacturers for dedicated, scalable, and cGMP-grade manufacturing capacity and resources. Our team of gene therapy manufacturing experts work closely with our partners to ensure that manufacturing for each of our programs smoothly transitions from development through to commercialization.
AXO-AAV-GM1 and AXO-AAV-GM2:
cGMP vector manufacturing is ongoing to support the clinical programs.
Currently, we have a partnership with Yposkesi, a large gene therapy manufacturing facility in Europe with multiple decades of experience as a spinout of Genethon. Yposkesi has a reserved and prioritized capacity for cGMP-grade vector production with dedicated suite space. It also is able to scale-up to support our commercial registrational process.
cGMP vector manufacturing is ongoing at Oxford Biomedica to support the clinical program. Oxford Biomedica is a world-leading clinical and commercial manufacturer of lentiviral gene therapies with an ongoing scale-up in process. Oxford is expanding its suite space and is moving to suspension-based processes to support our initiation of dosing in our AXO-Lenti-PD pivotal program.